The key I think for the success of CGP is whether the company can differentiate themselves from current mainstream products. There is a plethora of competing products in the nasal sports dilator segment as well as the apnea and snoring markets. But focusing on the sports market CGP needs to under pin their marketing strategy with professional athlete representation. Without this I feel that CGP will continue to be 'another' product hence reflected as a penny dreadful stock on the exchange. At the end of the day Rhino Med is still a commodity product and even with quality athlete representation CGP as an investment still equates to a lot of fundamental risk. This thesis is purely based on the growth in sales that eventual lead to cash earnings.
However on a technical note it seems positive with the product ramp up but I would prefer to have both positive fundamental and technical indicators.
Any comments on my thoughts will be appreciated.
CGP Price at posting:
3.9¢ Sentiment: None Disclosure: Not Held
